Literature DB >> 10357831

Transgenic mice expressing a human apolipoprotein[a] allele.

F Acquati1, R Hammer, B Ercoli, V Mooser, R Tao, V Rönicke, A Michalich, G Chiesa, R Taramelli, H H Hobbs, H J Müller.   

Abstract

The most important determinant of plasma levels of Lp[a] are sequence differences at the highly polymorphic apolipoprotein[a] (apo[a]) locus. To define the sequences that mediate the regulation of apo[a] expression, we cloned a 370 kb DNA fragment that included a 130 kb apo[a] gene, and 40 kb 5'- and 200 kb 3'-flanking region from an individual with high plasma levels of Lp[a] using a YAC vector. This genomic clone was used to generate transgenic mice. In the YAC-apo[a] transgenic mouse, apo[a] was only expressed in the liver, as it is in humans. The mean serum level of apo[a] in 4-week-old YAC-apo[a] transgenic mice was 20 mg/dl. In the female mice the levels of apo[a] varied over a 1.5-fold range during the 4-day estrus cycle and the levels correlated directly with serum progesterone levels. The serum levels of apo[a] decreased to almost undetectable level in male mice after puberty and this decrease was reversed by castration. Ingestion of a high-fat diet resulted in a approximately 100-fold fall in hepatic apo[a] mRNA levels and >60-fold decrease in serum apo[a] levels. To delimit the control elements that mediate tissue-specific and sex hormone-responsive apo[a] transcription, we derived a reporter YAC in which 40 kb of 5' flanking sequences from the cloned apo[a] allele were linked to a luciferase reporter gene. Analysis of four independent transgenic lines revealed no hepatic luciferase expression, suggesting that important cis -acting elements located outside the apo[a] 5'-flanking region are necessary for in vivo expression of apo[a].

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10357831

Source DB:  PubMed          Journal:  J Lipid Res        ISSN: 0022-2275            Impact factor:   5.922


  5 in total

1.  Hypoascorbemia induces atherosclerosis and vascular deposition of lipoprotein(a) in transgenic mice.

Authors:  John Cha; Aleksandra Niedzwiecki; Matthias Rath
Journal:  Am J Cardiovasc Dis       Date:  2015-03-20

Review 2.  Size matters: use of YACs, BACs and PACs in transgenic animals.

Authors:  P Giraldo; L Montoliu
Journal:  Transgenic Res       Date:  2001-04       Impact factor: 2.788

3.  Lipoprotein(a) promotes smooth muscle cell proliferation and dedifferentiation in atherosclerotic lesions of human apo(a) transgenic rabbits.

Authors:  Tomonaga Ichikawa; Hiroyuki Unoki; Huijun Sun; Hiroaki Shimoyamada; Santica Marcovina; Hisataka Shikama; Teruo Watanabe; Jianglin Fan
Journal:  Am J Pathol       Date:  2002-01       Impact factor: 4.307

Review 4.  Lipoprotein(a) beyond the kringle IV repeat polymorphism: The complexity of genetic variation in the LPA gene.

Authors:  Stefan Coassin; Florian Kronenberg
Journal:  Atherosclerosis       Date:  2022-05       Impact factor: 6.847

5.  Human apoB contributes to increased serum total apo(a) level in LPA transgenic mice.

Authors:  Päivi A Teivainen; Knut A Eliassen; Edward M Rubin; Srdjan Djurovic; Kåre Berg
Journal:  Lipids Health Dis       Date:  2004-05-11       Impact factor: 3.876

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.